A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer

Inclusion Criteria: * Histologically confirmed diagnosis of high grade serous or Grade 2/3 endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer； * Confirmed documented BRCA1/2 mutation; * Received 2\~4 prior chemotherapy regimens. Non-chemotherapy regimens and maintenance therapies administered as single agent treatment will not count as a chemotherapy regimen； * Relapsed/progressive disease as confirmed by radiologic assessment； * Have measurable disease as defined by RECIST v1.1. Exclusion Criteria: * Any previous treatment with a PARP inhibitor; * Patient with any other malignancy which has been active or treated within the previous 5 years; * Patients with symptomatic uncontrolled brain metastases; * Patients unable to swallow orally administered medication.